Closely-held Zucara Therapeutics received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes.
“GlycoNet’s and Mitacs’s first grants, announced in July 2019 and November 2020, respectively, enabled us to extend our preclinical model of hypoglycemia in Type 1 diabetes to Type 2 diabetes and progress the program to where it is today,” Dr. Michael Riddell, chairman of Zucara’s clinical advisory board, said in a statement.
“These second grants further support our preclinical efficacy studies which, if successful, will enable us to advance ZT-01 into clinical development in the Type 2 indication,” he added.
ZT-01 is currently in a Phase 1b proof-of-concept trial assessing the pharmacodynamics of treatment of insulin-induced hypoglycemia in people with Type 1 diabetes, with results anticipated in the second quarter of 2022.
